Summary
Hepatocellular adenomas (HCA) are rare benign liver tumors occurring in young women
taking contraception. They are associated with rare complications such as bleeding
or malignant transformation into hepatocellular carcinoma. A molecular classification
has divided HCA in several subgroups linked with risk factors, clinical behaviour,
histological features and imaging: HNF1A inactivated HCA, Inflammatory HCA, CTNNB1 mutated HCA in exon 3, CTNNB1 mutated in exon 7 and 8 HCA, sonic hedgehog HCA and unclassified HCA. CTNNB1 mutated HCA in exon 3 and sonic hedgehog HCA have been linked with a high risk of malignant
transformation and bleeding respectively. Herein, we review how molecular classification
has modified our understanding of the pathophysiology and risk factors of HCA development,
analysing its impact on clinical care in the field of diagnosis and therapeutic stratification.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of HepatologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Hepatocellular benign tumors-from molecular classification to personalized clinical care.Gastroenterology. 2013; 144: 888-902
- Diagnosis and management of solid benign liver lesions.Nat Rev Gastroenterol Hepatol. 2014; 11: 737-749
- Electronic address eee. EASL Clinical Practice Guidelines on the management of benign liver tumours.J Hepatol. 2016; 65: 386-398
- Liver-cell adenomas associated with use of oral contraceptives.N Engl J Med. 1976; 294: 470-472
- The association between oral contraception and hepatocellular adenoma–a preliminary report.Int J Gynaecol obstet. 1977; 15: 143-144
- Can a decision-making model be justified in the management of hepatocellular adenoma?.Liver Int. 2012; 32: 28-37
- Liver adenomatosis. An entity distinct from liver adenoma?.Gastroenterology. 1985; 89: 1132-1138
- Revisiting the pathology of resected benign hepatocellular nodules using new immunohistochemical markers.Semin Liver Dis. 2011; 31: 91-103
- Systematic review of haemorrhage and rupture of hepatocellular adenomas.Br J Surg. 2012; 99: 911-916
- A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas.Gastroenterology. 2009; 137: 1698-1705
- Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC.Hepatology. 2006; 43: 515-524
- Changing trends in malignant transformation of hepatocellular adenoma.Gut. 2011; 60: 85-89
- Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation.Gastroenterology. 2017; 152 (Epub 2016 Dec 7): 880-894.e6https://doi.org/10.1053/j.gastro.2016.11.042
- Bi-allelic inactivation of TCF1 in hepatic adenomas.Nat Genet. 2002; 32: 312-315
- HNF1alpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation.J Biol Chem. 2007; 282: 14437-14446
- Loss of hepatocyte nuclear factor 1alpha function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis.Hepatology. 2010; 51: 557-566
- Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene.Hepatology. 2009; 49: 821-831
- Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry.Hepatology. 2007; 46: 740-748
- Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience.Hepatology. 2009; 50: 481-489
- Genotype-phenotype correlation of CTNNB1 mutations reveals different ss-catenin activity associated with liver tumor progression.Hepatology. 2016; 64 (Epub 2016 Jun 11): 2047-2061https://doi.org/10.1002/hep.28638
- Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation.Cancer Cell. 2014; 25: 428-441
- Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours.Nature. 2009; 457: 200-204
- Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver.Gastroenterology. 2005; 128: 1211-1218
- Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma.Gastroenterology. 2004; 126: 1323-1329
- Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas.J Exp Med. 2011; 208: 1359-1366
- GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation.J Hepatol. 2012; 56: 184-191
- Inflammatory syndrome with liver adenomatosis: the beneficial effects of surgical management.Gut. 2007; 56: 307-309
- Telangiectatic adenoma: an entity associated with increased body mass index and inflammation.Hepatology. 2007; 46: 140-146
- Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3).Nature. 1996; 384: 455-458
- Hepatocyte nuclear factor-1 alpha gene inactivation: cosegregation between liver adenomatosis and diabetes phenotypes in two maturity-onset diabetes of the young (MODY)3 families.J Clin Endocrinol Metab. 2004; 89: 1476-1480
- Familial liver adenomatosis associated with hepatocyte nuclear factor 1alpha inactivation.Gastroenterology. 2003; 125: 1470-1475
- Primary hepatocellular neoplasms in a MODY3 family with a novel HNF1 A germline mutation.J Hepatol. 2013; 59: 904-907
- Regressive liver adenomatosis following androgenic progestin therapy withdrawal: a case report with a 10-year follow-up and a molecular analysis.Eur J Endocrinol. 2007; 156: 617-621
- Inflammatory hepatocellular adenomas developed in the setting of chronic liver disease and cirrhosis.Modern Pathol. 2016; 29: 43-50
- A serum amyloid A-positive hepatocellular neoplasm arising in alcoholic cirrhosis: a previously unrecognized type of inflammatory hepatocellular tumor.Modern Pathol. 2012; 25: 1584-1593
- Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I.J Hepatol. 2013; 58: 350-357
- Hepatocellular nodules expressing markers of hepatocellular adenomas in Budd- Chiari syndrome and other rare hepatic vascular disorders.J Hepatol. 2015; 63 (Epub 2015 Jun 25): 1173-1180https://doi.org/10.1016/j.jhep.2015.06.017
- Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification.Hepatology. 2008; 48: 808-818
- Hepatocellular adenomas: accuracy of magnetic resonance imaging and liver biopsy in subtype classification.Hepatology. 2011; 53: 1182-1191
- Hepatocellular adenomas: correlation of MR imaging findings with pathologic subtype classification.Radiology. 2011; 261: 172-181
- Inflammatory hepatocellular adenomas can mimic focal nodular hyperplasia on gadoxetic acid-enhanced MRI.AJR Am J Roentgenol. 2014; 203: W408-W414
- Differentiation of focal nodular hyperplasia from hepatocellular adenoma: Role of the quantitative analysis of gadobenate dimeglumine-enhanced hepatobiliary phase MRI.J Magn Reson Imaging. 2015; 42: 1249-1258
- Morphologic and molecular features of hepatocellular adenoma with gadoxetic acid-enhanced mr imaging.Radiology. 2015; 277: 104-113
- Management of focal nodular hyperplasia and hepatocellular adenoma in young women: a series of 41 patients with clinical, radiological, and pathological correlations.Hepatology. 1995; 22: 1674-1681
- Immunohistochemical markers on needle biopsies are helpful for the diagnosis of focal nodular hyperplasia and hepatocellular adenoma subtypes.Am J Surg Pathol. 2012; 36: 1691-1699
- Liver adenomatosis: reappraisal, diagnosis, and surgical management: eight new cases and review of the literature.Ann Surg. 2000; 231: 74-81
- Liver transplantation for adenomatosis: European experience.Liver Transpl. 2016; 22: 516-526
- Open and laparoscopic resection of hepatocellular adenoma: trends over 23 years at a specialist hepatobiliary unit.HPB. 2014; 16: 783-788
- Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma.Oncoimmunology. 2013; 2: e27090
- WNT/beta-catenin signaling in liver health and disease.Hepatology. 2007; 45: 1298-1305
- Efficacy and safety of vismodegib in advanced basal-cell carcinoma.N Engl J Med. 2012; 366: 2171-2179
- Unraveling the therapeutic potential of the Hedgehog pathway in cancer.Nat Med. 2013; 19: 1410-1422
- Validation of a liver adenoma classification system in a tertiary referral centre: implications for clinical practice.J Hepatol. 2011; 55: 120-125
- Genetic landscape and biomarkers of hepatocellular carcinoma.Gastroenterology. 2015; 149 (e1224): 1226-1239
- Risk factors for bleeding in hepatocellular adenoma.Br J Surg. 2014; 101: 847-855
- Will weight loss become a future treatment of hepatocellular adenoma in obese patients?.Liver Int. 2015; 35: 2228-2232
Article info
Publication history
Published online: July 18, 2017
Accepted:
July 11,
2017
Received in revised form:
May 29,
2017
Received:
March 29,
2017
Identification
Copyright
© 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
